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Abstract
Mice lacking the p27
Kip1 Cdk inhibitor (Cdkn1b) exhibit increased susceptibility to lymphomas from the Maloney murine
leukemia virus (M-MuLV), and exhibit a high frequency of viral integrations at Xpcl1 (Kis2), a locus on the X-chromosome.
Xpcl1 encodes miR-106a,363, a cluster of microRNAs that are expressed in response to adjacent retroviral integrations. We
report the first large-scale profile of microRNA expression in MuLV-induced lymphomas, in combination with microarray
gene expression analysis. The source material was T-cell lymphomas induced by M-MuLV in p27
Kip1 knockout mice and
normal thymus. Surprisingly, the overall levels of miRNA expression were equivalent in lymphomas and normal thymus.
Nonetheless, the expression of specific microRNAs was altered in tumors. The miR-106a,363 miRNA were over-expressed in
lymphomas, particularly those with viral integrations at the Xpcl1 locus. In contrast, p27
Kip1 deletion itself was associated
with a different pattern of microRNA expression. Gene expression was dramatically altered in lymphomas, yet paralleled
data from T-cell lymphomas induced by other mechanisms. Genes with altered expression in association with the p27
Kip1
null genotype were of similar functional classes to those associated with Xpcl1 integration, but with the opposite pattern of
expression. Thus, the effect of p27
Kip1 deletion may be to oppose an anti-oncogenic effect of Xpcl1 rather than enhancing its
oncogenic functions. A subset of miR-106a,363 target genes was consistently reduced in lymphomas with Xpcl1
integrations, particularly genes with cell cycle and immune functions. We identify four predicted target genes of miR-
106a,363 miRNA, including N-Myc (Mycn), and the TGF-beta receptor (Tgfbr2) using 3’UTR reporter assays. Still,
bioinformatic miRNA target predictions were poor predictors of altered gene expression in lymphomas with Xpcl1
integration. Confirmation of miR-106a,363 gene targeting relevant to the tumor phenotype requires in vivo validation,
because only a subset of predicted targets are consistently reduced in tumors that overexpress miR-106a,363.
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Introduction
Mice lacking one or both copies of the p27
Kip1 Cdk inhibitor are
susceptible to developing a variety of tumor types when exposed to
mutagenic agents. [1,2] Several oncogenes and tumor suppressor
genes have been shown to cooperate with p27
Kip1 loss, including
PTEN and APC, in the induction of breast, colon and prostate
cancers in mouse models. [2–4] We previously identified Xpcl1 as a
common viral integration site in T-cell lymphomas induced by
Moloney murine leukemia virus (M-MuLV) infection. M-MuLV
integrations targeted Xpcl1 at a higher frequently in tumors
induced in p27
Kip1 knockout mice. This finding suggested that
p27
Kip1 deletion cooperates with Xpcl1 activation in tumorigenesis,
thus the region was referred to as the X-chromosome p27 cooperating
locus. [5] Expression of a non-coding RNA from this locus was
increased in tumors with Xpcl1 integrations, and this was higher
than levels expressed in normal thymic tissue. Xpcl1 is not
exclusively targeted by M-MuLV in mice with p27
Kip1 deletions; it
has also been identified as a viral integration site in p27+/2 and
wildtype animals. [5,6] Likewise, integrations of other retroviruses,
RadLV and SL3-3, have been independently reported to map to
the same X-chromosomal site in murine lymphomas. [7,8] These
integrations were associated with increased expression of a cluster
of additional non-coding RNA splice variants, proximal to the
viral integrations that were collectively referred to as Kis2.
Mapping of microRNA sequences to the murine and human
genomes identified the locus as the coding sequence for a cluster
of five microRNAs, commonly referred to as miR-106a,363,
which span the proximal and distal EST clusters. [9] Thus the
normal gene, herein referred to as Xpcl1, apparently produces a
primary transcript that is cleaved to form component pre-miRNA
hairpins, as well as the flanking ESTs. Indeed, the individual
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e14758microRNA comprising miR-106a,363 have been shown to be
increased in tumors with viral integrations at the locus. [8,10]
Large scale viral mutagenesis screens identified increased
cointegration of retroviruses at Xpcl1 and cyclin D3 loci, which
further suggests an interaction between the Rb pathway with
Xpcl1 in tumorigenesis. [11]
MicroRNAs are products of RNA precursors transcribed by
RNA polymerase II and cleaved by the nuclear microprocessor
complex, which is comprised of the RNAse III, Drosha, and
DGCR8/Pasha, yielding 50280 bp stem-loop pre-miRNA (re-
viewed by R. Shivdasani). [12] Cytoplasmic Dicer further cleaves
the hairpin structures off pre-miRNA producing double stranded
RNA that includes the mature 20222 bp microRNA product.
Mature miRNA enter the RNA induced silencing complex
(RISC), where recognition or target mRNA sequences may lead
to translational silencing or degradation of mRNA targets. [13]
The miRBase database currently lists 600 microRNAs in the
mouse genome. [14] MicroRNA have been shown to impact a
wide variety of physiological activities including developmental
timing, cell proliferation, cell death, and hematopoiesis through a
combination of direct effects on target gene expression and a
cascade of secondary effects. [15] The first oncogenic non-protein
encoding RNA discovered was BIC, which lies at a common
integration site of the avian leukosis virus, and encodes miR-155.
[16,17] MiR-155 is overexpressed in a variety of human B-cell
lymphomas, and BIC overexpression induced lymphomas in
transgenic mice. [18–20] Human B-cell lymphomas have also
been shown to harbor gene rearrangements involving the miR-
17,92 microRNA cluster, which is a paralog of miR-106a,363.
Overexpression of miR-17,92 in transgenic mice increased the
rate of Myc-induced lymphomas and was associated with reduced
apoptosis, whereas cells lacking miR-17,92 are prone to Myc
induced apoptosis. [21,22]
It has been reported that tumor cells exhibit a global reduction
in miRNA expression compared to normal tissues, and that
impairment of the miRNA processing machinery is oncogenic.
[23,24] Yet, little is known about the global patterns of miRNA or
protein-coding gene expression in lymphomas induced by murine
retroviruses. A hypothesis of the current work is that genetic
alterations of M-MuLV induced lymphomas would result in
characteristic phenotypic patterns of miRNA and protein-coding
gene expression. Deletion of p27
Kip1 has been shown to be
associated with more rapid M-MuLV-induced lymphoma devel-
opment, with a higher frequency of viral integrations at Xpcl1.W e
therefore hypothesized that the gene expression phenotype
associated with p27
Kip1 deletion in tumors would reflect an
enhancement of the tumor phenotype, or an enhancement of
the miRNA or gene expression profile specific to Xpcl1. The classes
of genes associated with p27
Kip1 loss or Xpcl1 activation may give
clues to the altered functions associated with these mutations.
Herein, we report the results of both a miRNA and a protein-
coding gene expression analysis from M-MuLV induced T-cell
lymphomas. We also validate the targeting of four genes by
miRNA from the miR-106a,363 cluster.
Results
Global miRNA expression in lymphomas vs. normal
thymus
Global assessments of microRNA expression have not been
reported in MuLV-induced lymphomas. In this study, we used a
qPCR platform (previously described) to assess expression of 188
microRNAs. [25] The source material was T-cell lymphomas that
had been induced by the M-MuLV infection of mice, with or
without p27
Kip1 knockout mutations, in F1 hybrid (C57BL/6J 6
129S4) mice, as well as normal thymus controls. Retroviral
integration sites were previously mapped in these samples, and
integrations at the Xpcl1 locus were identified in tumors from
p27
Kip1 null animals, as well as in tumors arising in mice with one
or more intact copies of p27
Kip1. [5,6] (The complete dataset is
given in Table S1) We first compared the global miRNA
expression profile of all tumors in comparison with normal murine
thymus. The abundance of specific microRNAs varied over a wide
range (Figure 1A). In keeping with what has been reported in
human cancers, we found that the majority of microRNAs were
reduced in lymphomas relative to total RNA input. [24] However,
this approach does not consider the fact that lymphoma cells have
a higher total RNA content than does normal thymocytes. We
therefore measured the RNA and DNA content in each tumor and
compared this to normal thymic tissue. On average, the
lymphomas contained 1.9-fold more RNA relative to tissue mass,
and relative to genomic DNA mass. Considering that M-MuLV
tumors are near diploid, we conclude that there was nearly a two-
fold increase in total RNA per cell in the lymphomas. [26] When
adjusting for the total RNA content per cell, we find that the
number of miRNAs significantly increased in lymphomas is
comparable to the number that are decreased (Figure 1B).
Likewise, the sum total quantity of miRNA in lymphomas was
equivalent to normal tissue (Fold change=1.0860.05, tumor vs.
normal, mean 6 SE) when considered on a per cell basis.
miRNA associated with p27
Kip1 null genotype and Xpcl1
integrations
Amongst tumor samples, we compared the global microRNA
expression profiles associated with p27
Kip1 genotype (p27
Kip1 null vs.
wildtype), as well as the status of viral integrations at Xpcl1 (positive
or negative). Unsupervised hierarchical clustering based on
abundance of individual miRNA (not shown) did not strictly
segregate tumor samples either by p27
Kip1 genotype or by Xpcl1
integration. This indicates that, for the majority of miRNA,
neither of these factors are the major determinant of variability.
Nonetheless, some of the most striking changes in miRNA
expression in lymphomas included the microRNA encoded by
the miR-106a-363 cluster (Figure 1B). Using a supervised analysis
algorithm (PAM), we tested the hypothesis that viral integrations at
Xpcl1 are associated with expression of a distinct set of miRNA.
The median false positive discovery rate (FDR) was zero at up to 5
microRNAs but rose sharply at higher numbers. This indicates
that there are only 5 microRNAs (miR-363, miR-92-2, miR-20b,
miR-19b, and miR-106a) influenced by viral integration at Xpcl1
(Figure 1D). Sequence of a sixth microRNA, miR-18b, also lies in
the cluster but it was not increased in Xpcl1+ tumors relative to
Xpc1- tumors. Thus, the increased miR-18 levels noted in tumors
(Figure 1B), may be due to expression from paralogous miR-
17,92 cluster. One potential mechanism of cooperation would be
if p27
Kip1 deletion increased Xpcl1 expression, e.g. by increasing
expression following retroviral gene insertions or by increasing the
miRNA stability. Therefore, we asked whether homozygous
deletion of p27
Kip1 was associated with altered miRNA expression
in tumor samples. A supervised analysis (Figure 1C) suggests that 9
microRNAs were associated with the p27
Kip1 null genotype, with
considerable variability (FDR 30%). However, this list of miRNAs
does not include those from the miR-106a,363 cluster. Likewise,
limiting the analysis to tumors without Xpcl1 integrations, also does
not identify miR-106a,363 microRNA associated with the
absence of p27
Kip1 (not shown). Thus, p27
Kip1 deletion does not
appear to augment miR-106a,363 expression in lymphomas, but
it may induce increases in other miRNAs.
Xpcl1 and p27
Kip1 in Lymphoma
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Because gene expression profiles have not been reported for M-
MuLV induced lymphomas, we compared the general pattern of
gene expression in tumors compared to normal thymic tissue. Our
analysis normalized expression values within samples, as a function
of both expression intensities, and 2-dimensional feature locations.
[27] A supervised analysis (PAM) was used to identify genes
differentially expressed in tumors (Figure 2) compared to normal
thymus. In addition, tumors showed more heterogeneity of
expression compared to normal tissue. In order to determine
whether the pattern of expression seen in M-MuLV tumors was
similar to other T-cell lymphomas we compared our data to that
previously reported for T-cell lymphomas arising in mice with a ß-
catenin mutation. [28] We observed a high degree of correlation
across the two data sets, which is shown in Figure 2B, a plot of
expression rankings. The correlation is readily apparent as an
Figure 1. Expression of miRNA in M-MuLV lymphomas. The overall abundance and distribution of expression of individual miRNA species in
(A) lymphomas, compared to normal thymus, is similar but varies over a wide range. Concentration is expressed as copies per 10 pg or input RNA. Of
the 62 miRNA with expression levels.250 copies/cell (B) the majority show increased expression in tumors. (Levels displayed as the fold change of
copies per tumor cell relative to copies per normal thymocyte, on a log2 scale). All 5 miRNA from the miR-106a,363 cluster (green) are increased in
tumors. The dashed red line shows magnitude of baseline shift resulting from a mean 1.9-fold increase in total RNA in tumors vs. normal thymus.
Every miRNA value below this line is reduced relative to the increased total RNA content of tumor cells. Nine miRNA altered in association with p27
Kip1
genotype are shown in a heatmap (C) reflecting the relative abundance of each miRNA across tumor samples. Heatmap of five miRNA (D) with
changes associated with Xpcl1 viral integration status. All 5 are increased and are members of the miR-106a,363 cluster.
doi:10.1371/journal.pone.0014758.g001
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quadrants (R
2=0.45, p,2610
216 Pearson correlation). In a gene
ontology assessment, the biological function terms for DNA and
protein metabolism and the cell division cycle, were enriched
amongst genes with high levels of expression in tumors on either
platform. In contrast, T-cell function and intracellular signaling
terms were enriched in the genes with reduced expression in
lymphomas (Table S2). We refer to this altered pattern of gene
expression as the lymphoma expression phenotype.
Gene expression profiles of p27
Kip1 null and Xpcl1+ tumors
To determine whether expression of specific classes of genes is
associated with p27
Kip1 genotype, we compared the microarray
expression profiles of lymphomas from p27
Kip1 null animals to
tumors from mice with one or two copies of p27
Kip1. We ranked
genes according to their PAM score, then tested for enrichment of
gene ontology terms for the top 10% of genes altered in p27
Kip1
null tumors, using the Panther gene classification system. [29] In
this analysis, statistical significance is a function of both the relative
enrichment of classification terms and the size of the gene class, so
we displayed results in circle plots (Figure 3A–C) showing all three
parameters. Interestingly, the classes of genes enriched in p27
Kip1
null tumors were similar to those enriched in tumors in general
(Figure 3A,B and Table S2), suggesting that the p27
Kip1 null tumors
had a more pronounced lymphoma expression phenotype. In a
separate analysis, we compared the patterns of gene expression in
Figure 2. Patterns of mRNA expression in M-MuLV induced lymphomas. A heatmap (A) of the mRNA expression in 22 samples, showing
both lymphomas (right) compared to normal thymus (left). The top 5000 genes (in terms of statistical significance) that display altered expression in
tumors compared to normal thymus are shown. Expression levels are relative to gene-specific means, and are displayed log2 scale of microarray spot
intensities (green = decreased, red = increased). A strong association of gene expression (B) in M-MuLV-induced lymphomas and ß-catenin-induced
lymphomas is seen in a plot of expression rankings. The 9804 genes with the highest levels of expression are shown color coded by plot density (left
lower quadrant = reduced gene expression in tumors on both platforms, right upper quadrant = increased expression). An even distribution of
points across all four quadrants would be expected if there is no association in tumor gene expression between the two tumor types. A heatmap of
250 genes (C) whose expression is most strongly associated with tumors containing Xpcl1 viral integration (+) vs. tumors without Xpcl1 integration
(2). Gene names are given for selected Xpcl1 predicted target genes.
doi:10.1371/journal.pone.0014758.g002
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tions, using an identical approach. There was partial overlap
between Xpcl1 and p27
Kip1 genotypes, with 5 out of 8 Xpcl1+
tumors lacking p27
Kip1, and 4 out of 9 Xpcl1- tumors lacking
p27
Kip1. For this reason, a slight resemblance between the classes of
genes associated with p27
Kip1 loss and Xpcl1 integration might be
expected. To the contrary, the functional classes associated with
p27
Kip1 null tumors showed the opposite pattern of expression in
Xpcl1+ tumors. For example, the cell cycle term was enriched
amongst genes with increased expression in p27
Kip1 null tumors,
but it was also enriched amongst genes decreased in Xpcl1+ tumors
(Figure 3B,C and Table S2). The opposite was true for genes in the
Immunity and Defense category. These differences were largely
due to changes in non-overlapping genes, as highlighted in the
Venn diagram (Figure 3D), which further suggests that this
observation is not simply due to the overlapping sample groups.
To confirm the accuracy of the array results we verified, by qPCR,
the RNA levels of 14 genes associated with Xpcl1 integrations.
There was a strong correlation (R
2=0.91, p=5610
26, Pearson
correlation) between mean expression levels determined by the
microarrays and the qPCR assays (Figure 4A).
Xpcl1 target gene expression
To test the hypothesis that miRNA expression was associated
with reduced expression of predicted target genes we analyzed
expression of genes that are predicted targets of microRNAs
overexpressed in tumors with Xpcl1 locus integrations, and
microRNAs associated with p27
Kip1 genotype. Within tumors, a
number of miR-106a,363 target genes displayed reduced
expression in association with Xpcl1 integration. Of 500 Xpcl1
predicted targets decreased in tumors with Xpcl1 viral integrations
there was relative enrichment for the terms Oncogenesis, and Cell
Cycle (Table 1). We cloned the 3’UTR of four predicted target
genes (Figure 4B,C), which showed varying levels of reduced
expression in tumors, into a luciferase reporter constructs. This
included two genes (N-myc and Grsf1) that were reduced in
association with Xpcl1 viral integration, and two genes (Tgfbr2 and
Nfat5) that were not. In each case, cotransfection of a genomic
fragment of Xpcl1 reduced expression of the 3’UTR reporter
constructs. Mutation of miRNA binding site seed regions in the
3’UTR eliminated the effect of miR-106a,363 on the expression
of Nfat5 and N-myc, but did not restore Grsf1 expression. In the case
of Tgfbr2, miR-106a,363 decreased the expression level of the
endogenous Tgfbr2 mRNA and decreased TGF-beta signaling as
measured by the p3TP-Lux reporter construct (Figure 4D). Still,
the majority of miR-106a,363 predicted targets did not show a
significant reduction at the RNA level in tumors with viral
integration at Xpcl1 (See Figure 4A and Table S3).
Discussion
A principal aim of this study was to determine the pattern of
miRNA and protein coding gene expression associated with
p27
Kip1 deletion or Xpcl1 activation in M-MuLV lymphomas. Our
initial hypothesis was that the two events would be associated with
the activation of genes with similar functions, or in activities
complementary for tumor development. Despite the extensive use
of retroviral mutagenesis in mouse models, neither miRNA nor
gene expression profiles have been previously reported. Thus, we
felt it was imperative to observe the general patterns of gene
expression in M-MuLV induced tumors compared to normal
tissue, and determine whether this profile is comparable to T-cell
lymphomas induced by other mechanisms. We found a global
reduction in the miRNA/ total RNA ratio in tumors compared to
normal thymic tissue, which is analogous to what has been
described in human cancer. [24] However, it has long been
recognized that proliferating cells, in general, and cancer cells, in
Figure 3. Gene expression associated with Xpcl1 integration and p27
Kip1 null genotype. Biological function classes of the top 2500 genes
associated with M-MuLV tumors vs. normal thymus (A) are shown in a circle plot with statistical significance plotted on the Y-axis and relative
enrichment (observed/expected) plotted on the X-axis. Genes showing increased expression are shown (red) to the right and those with decreased
expression (green) are plotted left of the Y-axis (P-values, binomial test). Circle diameters are proportional to the number of genes observed in each
group. Within tumor samples, the functional classification of genes associated with (B) p27
Kip1 null genotype or (C) Xpcl1 integrations are shown. A
Venn diagram (D) shows limited overlap amongst genes exhibiting decreased expression in association with Xpcl1 integration (Xpcl1 Low) and
simultaneously showing increased expression in p27
Kip1 null tumors (KO High) (n=30). Likewise, there is little overlap between the Xpcl1 High vs. KO
Low sets (n=37).
doi:10.1371/journal.pone.0014758.g003
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therefore quantified the total RNA abundance in our M-MuLV
lymphoma specimens, and found that the apparent change in
global miRNA levels was entirely attributable to the increased total
cellular RNA in tumors. Thus, it should not be assumed that
reduced miRNA levels are a general characteristic of tumors, if the
data is not adjusted to cell number. Still, in terms of biological
impact, a decrease in the ratio of miRNA/total RNA may have
the same implications as a drop in absolute miRNA abundance.
The stoichiometry of miRNA compared to the expression of their
target genes is likely a key determinant of miRNA effectiveness. In
contrast to the lack of change of global miRNA levels, the pattern
of individual microRNA expression was highly distinctive in
tumors. A large numbers of microRNA were significantly changed
(both up and down) compared to normal thymus.
We found that, of the 188 miRNA queried, the only miRNAs
significantly altered in association with Xpcl1 are members of the
miR-106a,363 cluster. This reinforces observations reported for
the radiation leukemia virus and SL3-3, which were also shown to
be associated with increased miR-106a,363 miRNA expression.
[8,10] Not all of the miR-106a,363 miRNA sequences are
unique. However, the fact that we see overexpression of miR-363
(which is unique to this cluster) shows that the cluster is
overexpressed. Mir-18, in contrast, is also encoded by the
paralogous miR-17,92 cluster. We observed increased expression
of miR-18 in lymphomas, compared to normal thymic tissue.
However, there was no further increase in miR-18 levels in tumors
with Xpcl1 integrations, so this likely represents expression from
the miR-17,92 paralog. The broad array of miRNAs sampled
here indicates the specificity of the effect of Xpc1 integration on
miR-106a,363, and argues against a general effect on miRNA
expression. Deletion of p27
Kip1 did not independently increase the
Figure 4. Effect of Xpcl1 on target gene expression. (A) Differences in mRNA expression was measured by qPCR (mean -DDCt) for 17 genes and
plotted as the mean difference in PCR cycle number of Xpcl1 positive vs. Xpcl1 negative tumors. This correlated with the changes in genes expression
noted on microarrays (mean M, log2(tumor/normal)). Genes with varying levels of change in association with Xpcl1 integration are shown, some of
which are predicted targets of miR-106a,363 (red) and others which are not (blue). Comparison of luciferase activity (B) in reporter constructs
containing 3’UTR sequences of miR-106a,363 predicted target genes: Nfat5, N-myc, and Grsf1. Each 3’UTR reporter construct was cotransfected with
either pCIG-Xpcl1 or empty pCIG vector. Xpcl1 was also transfected with reporter constructs with mutations in the seed region of the predicted
miRNA target site (D3’UTR). Xpcl1 expression reduces luciferase expression associated with the 3’UTR of Tgfbr2 (C), and results in reduced Tgfbr2
mRNA levels as measured by qPCR. Xpcl1 reduces downstream signaling in response to TGF-beta (right panel C) as measured by activity of the 3T3-
Lux reporter construct. (Barplots are means 6 SE).
doi:10.1371/journal.pone.0014758.g004
Table 1. Biological Process of Xpcl1 targets with reduced
mRNA expression.
Xpcl1 Targets Observed Expected P-value
Oncogenesis 21 9 2.2E-02
Cell cycle 35 20 5.2E-02
Panther gene classification terms for the biological function of miR-106a,363
predicted target genes (n=500) that show reduced expression in tumors with
Xpcl1 viral integrations, relative to the superset of genes present on the
microarray. (P-values, binomial test).
doi:10.1371/journal.pone.0014758.t001
Xpcl1 and p27
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expression of a separate group of miRNAs. This argues against the
hypothesis that p27Kip1 cooperates with Xpcl1 simply by
enhancing the expression of its constituent miRNAs.
In the case of protein coding genes, we observed a massive shift in
the pattern of gene expression in M-MuLV induced T-cell
lymphomas compared to normal thymic tissue. These changes are
impressive when considered either on absolute terms (RNA per cell)
or on relative terms (when adjusted to RNA abundance). On
absolute terms, the overall abundance of RNA in tumors was 1.96
higher than in normal thymic tissue. Typically, expression data is
normalized in ways that sets median gene expression values to a set
value or, as in our case, sets the log ratios (sample vs. reference) to
zero. Based on our raw (pre-normalized) data, 94% of all Entrez
genes show significant increases in expression in tumors compared
to normal thymic tissue (data not shown). Although this figure
conveys the magnitude of shift in global RNA expression in tumor
cells, it belies the shift in the pattern of gene expression exhibited by
the tumors. In contrast, when expression data is subjected to
conventional normalization (disregarding differences in RNA
content per cell) we see that many genes exhibit relative decreases
as well as increases in expression (Figure 2A). The functional
classification of genes showing reduced expression in the lympho-
mas was frequently related to T-cell immunity (Figure 3A, Table
S2). This is consistent with lymphomas developing a de-differen-
tiated phenotype. Alternatively, it may reflect a reduced likelihood
of up-regulating genes not essential to tumor development. Despite
differences in array platforms, we observed a high level of similarity
in gene expression in our M-MuLV lymphomas compared to that
previously reported for lymphomas with a stabilizing mutation of ß-
catenin. [28] In both cases, genes involved with RNA and protein
metabolism were up-regulated; whereas genes involved with
immunity showed relatively reduced expression. We conclude that
the massive alteration in gene expression in M-MuLV induced
tumors is a common feature of murine T-cell lymphomas and is not
a peculiarity of M-MuLV tumor induction.
In comparison to other tumors, gene expression in p27
Kip1 null
tumors showed further reduction in expression of genes involved
with T-cell function (Figure 3). Thus, p27
Kip1 loss was associated
with both shortened survival and a further deviation from the
normal T-cell expression phenotype. [5] Interestingly, genes
associated with Xpcl1 retroviral integration showed the opposite
pattern of expression, even though Xpcl1 integration frequently
occurred in p27
Kip1 null animals. Our finding of a contrasting
pattern of expression associated with Xpcl1 genotype compared to
p27
Kip1 genotype does not support the hypothesis that loss of p27
Kip1
simply enhances Xpcl1’s expression phenotype. Because of sample
number limitations, our assessment did not include a pair-wise
comparison of all four subsets of tumor samples based on p27
Kip1
and Xpcl1 genotypes. Such an approach might better elucidate the
extent to which coincident mutation of p27
Kip1 modifies gene
expression changes by Xpcl1. Still, our data suggests that deletion of
p27
Kip1 counters an anti-oncogenic pattern of gene expression
induced by Xpcl1, rather than enhancing an oncogenic effect.
According tothe PicTar database3,269Entrez genes are predicted
targets of at least one of the miR-106a,363 miRNAs. Considering
the large number of predicted targets, it is expected that miR-
106a,363 expression would induce a combination of oncogenic and
anti-oncogeniceffects.Othershavedemonstratedcellularactivitiesby
miR-106a,363 (and its paralogous miRNA clusters) that are
potentially pro-oncogenic. This includes the demonstration that
anchorage independent growth is enhanced by miR-106a,363 as
well as direct targeting of Mylip and Rbp1-like gene expression. [10]
Likewise, miR-106a,363 and its paralogs have been shown to
promote proliferation of cultured cells by targeting p21
Cip1/Waf1 and
p63. [32,33] Thus it is somewhat surprising that our gene expression
observations suggest that, in terms of its interaction with Xpcl1,t h e
effect of p27
Kip1 loss is to overcome an anti-tumor activity of Xpcl1,a s
opposed to enhancing Xpcl1’s oncogenic effect.
In regards to the expression of miRNA target genes, we saw a
high frequency of reduced gene expression (52%) amongst genes
that are predicted targets of miR-106a,363. However, we also
observed a high frequency of reduced expression amongst miRNA
target genes in general, regardless of the expression levels of their
predicted effecter microRNAs. Thus, global reduction in miRNA
target gene expression appears to be an incidental aspect of the
tumor phenotype, although it might also result from secondary
effects of a few overexpressed microRNAs. Two predicted targets
of miR-106a,363 miRNA are N-myc and Grsf1, both of which
were decreased in Xpcl1 positive vs. Xpcl1 negative tumors. M-
MuLV integrations were present at the N-Myc locus in 3 of the
Xpcl1 negative tumors that we assayed (not shown). This may
partially explain the reduced levels of N-Myc that we observed in
Xpcl1 positive tumors. Additionally, forced expression of Xpcl1 in
cultured T-cells reduced expression of an N-Myc 3’UTR reporter
construct. This effect by Xpcl1 was eliminated by mutation of the
predicted miRNA target site in the N-Myc 3’UTR, which indicates
that the miRNAs directly target N-Myc. Reduced N-Myc
expression would be expected to have an anti-proliferative effect,
in part because N-Myc activates transcription of the Skp2 ubiquitin
ligase, which in turn degrades p27Kip1 protein. [34,35] Thus, the
targeting of N-Myc by Xpcl1 is one example of an anti-oncogenic
effect that may be overcome by p27Kip1 deletion.
Not all of the predicted targets of miR-106a,363 were
consistently reduced in tumors with Xpcl1 integrations. For
example, Tgfbr2, the TGF-ß cell surface receptor, is a predicted
target of both miR-19b and miR-106a, but was not significantly
changed in tumors with Xpcl1 integration. Nonetheless, luciferase
reporter assays indicate that the 3’UTR of Tgfbr2 does confer
sensitivity to Xpcl1 expression (Figure 4). Likewise forced
expression of Xpcl1 in cultured cells reduced both Tgfbr2 mRNA
levels and reduced signaling downstream of TGF-ß. To an extent,
the discrepancy between tumor RNA expression and the reporter
assay data may reflect the ability of the luciferase assay to detect
the combined effect of miRNA on both mRNA stability and
protein translation. However, endogenous gene expression is also
subject to secondary effects and compensatory changes, which
might easily overwhelm the comparatively subtle impact of
miRNA. Finally, the existence of cell-type or gene-specific
modifiers of miRNA function remains a possibility; so cultured
T-cells may not accurately reflect the situation in tumors. Our list
of miR-106a,363 predicted target genes, exhibiting reduced
expression in association with Xpcl1 integration, shortens the set of
genes likely to mediate the effect of miR-106a,363 on the tumor
phenotype. The confirmation of the oncogenic potential of Xpcl1
and the elucidation of its pathogenic mechanism would further
benefit from the in vivo manipulation of Xpcl1 expression in the
absence of other M-MuLV integrations. Given the complexity of
gene expression in tumors, and the subtle yet widespread effects of
miRNA expression, overexpression of Xpcl1 in primary cells will
likewise be important for the confirmation of physiologically
relevant miR-106a,363 targets.
Materials and Methods
Sample preparation and microRNA quantification
This work involved frozen tumor samples previously taken from
p27
Kip1 knockout mice (p272/2, p27+/2, and p27+/+) induced
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infection. These tumors were previously surveyed for the genomic
integration sites of M-MuLV proviruses and are thus characterized
with respect to the presence or absence of M-MuLV integrations
at the Xpcl1 locus (Xpcl1 positive), and Myc family members. For
this work tumor tissue was characterized as being p27null (2/2)
vs. not null (+/2 or +/+) and with respect to M-MuLV integration
at the Xpcl1 locus (positive or negative). [5] The prior animal work
was conducted according to national guidelines (OLAW) and
approved by the IACUC of the Fred Hutchinson Cancer
Research Center. Animals had been observed daily and were
euthanized if they developed signs of morbidity, palpable tumors
greater than 1 cm. diameter, or age .1 year. These tumors were
previously characterized for the presence of M-MuLV integrations
at the Xpcl1 locus. All animals were humanely euthanized with
CO2 or anesthetic inhalation. Frozen whole thymus from
uninfected animals (on the same 129S4 6 C57BL/6J F1 hybrid
strain background) was used for comparisons. Tissues were
divided, weighed and then extracted for either DNA or total
RNA. RNA was prepared with Trizol (Invitrogen) using 1.5
volumes of isopropanol to increase the efficiency of miRNA
precipitation. RNA and DNA were quantified using Ribogreen
(Invitrogen) fluorescence. Expression of individual miRNAs were
determined using a quantitative primer-extension PCR assay
(Table S1), as previously described. [36] Ct values were converted
to copy numbers by interpolation on standard curves generated
using single stranded mature miRNAs to calculate miRNA copies
per 10 pg of input RNA, and are given in Table S1. The total
RNA to DNA ratios of each tumor sample was determined by
purifying total RNA and genomic DNA from weighed samples
(,5 mg) under non-saturating conditions on nucleic acid biding
columns (RNeasy and DNeasy, QIAgen). Standard curves with 2-
fold dilutions (0.625–10 mg) of starting material demonstrated a
high degree of linearity with respect to the mass of starting
material (R
2=0.985 for RNA, R
2=0.984 for DNA). The pamr
software package for R (R-project.org, BioConductor.org) was
used to identify miRNA associated with Xpcl1 integration (Xpcl1+
vs. Xpcl12) and p27
Kip1 genotype (null vs. +/2 or +/+). [37] The
top miRNAs associated with p27
Kip1 genotype and Xpcl1
integration are shown in heatmaps where quantities of individual
miRNAs are displayed relative to the mean expression value of the
same miRNAs across all samples. Hierarchical clustering was used
to group samples post hoc using Cluster 3.0 software with
Euclidean distance and complete linkage.
Microarray analysis
Trizol prepped total RNA was additionally treated with
DNAseI (RNAse free, Roche) and purified with RNeasy mini
columns (Qiagen). RNA was amplified and labeled with Cy5 and
Cy3 as previously described. [25] Labeled RNA pooled from 17
tumor samples and 3 normal thymuses formed a common
reference and were co-hybridized vs. sample RNA in a two color
format on duplicate custom murine oligonucleotide arrays
(Agilent, GEO accession GPL8525) (n=40 arrays. See Table
S5 for complete sample descriptions). The genotypes of the
tumor samples were balanced with roughly half of the samples
(n=9) being p27
Kip1 null, and half of the samples containing
Xpcl1 viral integrations (n=8), 4 of which were both p27
Kip1 null
and Xpcl1+. (See Table S5 for detailed sample descriptions).
Log(2) ratios of fluorescence intensities (experimental sample vs.
pooled reference) were normalized by intensity-dependent Loess
followed by 2-dimensional location-dependent loess using the
marray Bioconductor package without local background subtrac-
tion or scaling. [27] Missing (software flagged features) values
were imputed by the K-nearest neighbor method, and genes
associated with tumors vs. normal were determined with the
PAM algorithm, using the pamr Bioconductor package. [38] We
compared relative gene expression of tumors vs. normal, ranked
by PAM-scores, to similarly processed raw data for ß-catenin
induced tumors obtained from the GEO repository. [28] Both
studies included normal thymus so we used this as a common
reference. Platform specific bias was avoided by comparing ranks
of expression data (expressed as log tumor/normal) and
calculating the geometric means across multiple samples. This
approach is equivalent to the Rank Product (RP) method, which
was shown to be robust for comparing gene expression profiles.
[39] Likewise, we analyzed our M-MuLV tumor data for genes
associated with either Xpcl1 integration or p27
Kip1 genotype
(PAM-scores listed in Table S3). Data processing was streamlined
with custom wrapper functions contained in the ArrayFun package
(available at http://labs.fhcrc.org/fero/R/ArrayFun.html). This
package includes functions, (array.getGEO, array.readGEO), that
downloads data from these 40 microarrays, along with the
sample description table, from the GEO FTP site directly into R.
Both MIAME compliant raw and normalized data are available
at the GEO data repository (accession GSE16005). [40] An R
script that outlines for obtaining raw data and recapitulates the
data processing steps is included as a supporting data file (Table
S6). We used the ‘‘compare gene list’’ tool of the Panther
Classification System (http://www.pantherdb.org) In order to
determine the enrichment of biological function terms in genes of
interest. [29] We input the top 2500 Entrez Gene IDs (ranked by
PAM scores, above) and compared this to the entire set genes on
the arrays. Terms over-represented in the genes of interest (p-
values#0.05, binomial test) are shown in Figure 3 and are listed
in Table S2.
MicroRNA target validation
129S4 mouse genomic Xpcl1 DNA was isolated from a phage
library. A 1.5 kB fragment containing the entire miR-106a,363
miRNA cluster was subcloned into pCIG (courtesy of Andy
McMahon) with the chicken B-actin promoter, the pSM30 vector
(courtesy of Muneesh Tewari) and the p1026x vector with the
Lck promoter (courtesy of Brian Iritani). [41–43] Genomic
3’UTR DNA segments for putative target genes (N-Myc, Tgfbr2,
Grsf1,a n dNfat5) were PCR amplified from mouse 129S4
genomic DNA, cloned into pGL3-control (Promega), a luciferase
reporter with the SV40 promoter, and verified by sequencing.
Three or four bases of miRNA seed sequence, in the UTR of
predicted target genes, were mutated using the QuickChange
Mutagenesis Kit (Agilent, #210513) with oligonucleotides, listed
in Table S4. Wildtype and mutant 3’UTR reporter constructs
were co-transfected (in triplicate) with pSM30-Xpcl1 vs. empty
vector and pRL-TK (Promega, renilla control) into 293T cells
using Lipofectamine 2000 (Invitrogen). Tgfbr2 3’UTR luciferase
assays compared pCIG-Xpcl1 vs. empty vector. Luciferase
activity was assayed at 48 hr. and adjusted by renilla activity.
To quantify the effect on Tgfbr2 mRNA expression and TGF-beta
signaling, murine SV40-180 T-cells were transfected by electro-
poration with either p1026x–Xpcl1 or empty vector. RNA was
isolated at 48 h and Tgfbr2 qPCR was done, as described above.
To measure TGF-beta signaling the p3TP-Lux reporter of TGF-
beta signaling (courtesy of William Grady) was additionally
transfected. The cells were treated with porcine TGF-beta 1
(5 ng/mL, R&D Systems) starting at 24 hrs. post-transfection and
luciferase activity was assayed at 48 h. [44] The transfection of
each construct and its controls were performed in triplicate or
quadruplicate.
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